Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) is one of 897 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Aquestive Therapeutics to similar businesses based on the strength of its valuation, profitability, institutional ownership, risk, earnings, analyst recommendations and dividends.
Valuation & Earnings
This table compares Aquestive Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Aquestive Therapeutics | $44.54 million | -$83.78 million | -5.98 |
| Aquestive Therapeutics Competitors | $3.54 billion | $3.17 billion | 546.63 |
Aquestive Therapeutics’ rivals have higher revenue and earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares Aquestive Therapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aquestive Therapeutics | -144.63% | N/A | -52.40% |
| Aquestive Therapeutics Competitors | -2,380.91% | -221.72% | -15.99% |
Analyst Recommendations
This is a breakdown of current ratings for Aquestive Therapeutics and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aquestive Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
| Aquestive Therapeutics Competitors | 7765 | 13847 | 25696 | 1031 | 2.41 |
Aquestive Therapeutics presently has a consensus price target of $8.60, indicating a potential upside of 121.08%. As a group, “Pharmaceuticals” companies have a potential upside of 23.97%. Given Aquestive Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Aquestive Therapeutics is more favorable than its rivals.
Insider & Institutional Ownership
32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 32.4% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Volatility and Risk
Aquestive Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Aquestive Therapeutics’ rivals have a beta of -4.31, suggesting that their average share price is 531% less volatile than the S&P 500.
Summary
Aquestive Therapeutics beats its rivals on 7 of the 13 factors compared.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
